{"id":9357,"date":"2024-10-18T12:13:01","date_gmt":"2024-10-18T19:13:01","guid":{"rendered":"https:\/\/www.breakthrought1d.org\/pacificnorthwest\/?p=9357"},"modified":"2026-05-21T17:07:31","modified_gmt":"2026-05-21T17:07:31","slug":"remodel-t1d","status":"publish","type":"post","link":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/","title":{"rendered":"REMODEL T1D"},"content":{"rendered":"<h2>Do you have Type 1 Diabetes and Diabetic Kidney Disease?<\/h2>\n<p>Kidney disease is common in <a href=\"https:\/\/www.breakthrought1d.org\/t1d-basics\/\">type 1 diabetes<\/a> (T1D). <a href=\"https:\/\/www.breakthrought1d.org\/t1d-resources\/complications\/kidney-disease\/\">Diabetic kidney disease<\/a> can cause many problems, such as kidney failure that needs dialysis or kidney transplantation, or damage to the heart and blood vessels that can lead to heart failure or stroke. That\u2019s why treatments that prevent and treat kidney disease in T1D are very important.<\/p>\n<p>The University of Washington (UW) is looking for participants for the REMODEL T1D study. The purpose of this study is to test whether semaglutide (commonly known as Ozempic) protects the kidneys in those with T1D. Semaglutide has been shown to reduce blood glucose and body weight and protect the kidneys in type 2 diabetes. It is possible that semaglutide has similar benefits in T1D, but this is not known. Because of this, the use of semaglutide in those with T1D, such as in this study, is experimental. The study will be conducted at the UW South Lake Union Diabetes Institute in Seattle.<\/p>\n<p>You may be eligible to join this study if:<\/p>\n<ul>\n<li>You are 18 years or older<\/li>\n<li>You have had Type 1 Diabetes greater than or equal to 5 years<\/li>\n<li>You have protein (albumin) in the urine<\/li>\n<li>Your A1C is less than 9%<\/li>\n<\/ul>\n<p>Procedures involved include:<\/p>\n<ul>\n<li>Blood draw<\/li>\n<li>Urine sample<\/li>\n<li>MRI<\/li>\n<li>Eye Exam<\/li>\n<li>Once weekly injections of semaglutide<\/li>\n<\/ul>\n<p>If interested, please contact the REMODEL T1D Research Coordinators at UW:<\/p>\n<ul>\n<li>Evelin Jones at <a href=\"mailto:evelinj@uw.edu\">evelinj@uw.edu<\/a>, <em><strong>or <\/strong><\/em><\/li>\n<li>Darinka Gil at <a href=\"mailto:dgm91@uw.edu\">dgm91@uw.edu<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Do you have Type 1 Diabetes and Diabetic Kidney Disease? Kidney disease is common in type 1 diabetes (T1D). Diabetic kidney disease can cause many problems, such as kidney failure that needs dialysis or kidney transplantation, or damage to the&hellip;<\/p>\n","protected":false},"author":1317,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ep_exclude_from_search":false,"publish_on_app_meta":"True","iawp_total_views":33,"footnotes":"","_members_access_role":[],"_members_access_error":"","bt1d_storytelling_post":false,"bt1d_storytelling_more_posts":[]},"topics":[16],"class_list":["post-9357","post","type-post","status-publish","format-standard","hentry","jdrf_topic-research"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>REMODEL T1D Semaglutide Kidney Study | Breakthrough T1D Greater Northwest<\/title>\n<meta name=\"description\" content=\"The University of Washington is enrolling type 1 diabetes patients with diabetic kidney disease for the REMODEL T1D trial. Learn how semaglutide is being evaluated to protect renal function and reduce albuminuria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"REMODEL T1D Semaglutide Kidney Study | Breakthrough T1D Greater Northwest\" \/>\n<meta property=\"og:description\" content=\"The University of Washington is enrolling type 1 diabetes patients with diabetic kidney disease for the REMODEL T1D trial. Learn how semaglutide is being evaluated to protect renal function and reduce albuminuria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Northwest Chapter\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/breakthrought1dHQ\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-18T19:13:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-21T17:07:31+00:00\" \/>\n<meta name=\"author\" content=\"Breakthrough T1D Author\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:site\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Breakthrough T1D Author\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/10\\\/18\\\/remodel-t1d\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/10\\\/18\\\/remodel-t1d\\\/\"},\"author\":{\"name\":\"Breakthrough T1D Author\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/person\\\/d91bebaf8f6259d18f7a0d24d101e6e6\"},\"headline\":\"REMODEL T1D\",\"datePublished\":\"2024-10-18T19:13:01+00:00\",\"dateModified\":\"2026-05-21T17:07:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/10\\\/18\\\/remodel-t1d\\\/\"},\"wordCount\":253,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/10\\\/18\\\/remodel-t1d\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/10\\\/18\\\/remodel-t1d\\\/\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/10\\\/18\\\/remodel-t1d\\\/\",\"name\":\"REMODEL T1D Semaglutide Kidney Study | Breakthrough T1D Greater Northwest\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#website\"},\"datePublished\":\"2024-10-18T19:13:01+00:00\",\"dateModified\":\"2026-05-21T17:07:31+00:00\",\"description\":\"The University of Washington is enrolling type 1 diabetes patients with diabetic kidney disease for the REMODEL T1D trial. Learn how semaglutide is being evaluated to protect renal function and reduce albuminuria.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/10\\\/18\\\/remodel-t1d\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/10\\\/18\\\/remodel-t1d\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/10\\\/18\\\/remodel-t1d\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"REMODEL T1D\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#website\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/\",\"name\":\"Greater Northwest Chapter\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/BT1D-favi.png\",\"contentUrl\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/BT1D-favi.png\",\"width\":400,\"height\":400,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/breakthrought1dHQ\",\"https:\\\/\\\/x.com\\\/breakthrought1d\",\"https:\\\/\\\/www.youtube.com\\\/@breakthrought1d\",\"https:\\\/\\\/www.instagram.com\\\/breakthrought1d\\\/\",\"https:\\\/\\\/www.tiktok.com\\\/@breakthrought1dhq\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/person\\\/d91bebaf8f6259d18f7a0d24d101e6e6\",\"name\":\"Breakthrough T1D Author\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"caption\":\"Breakthrough T1D Author\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"REMODEL T1D Semaglutide Kidney Study | Breakthrough T1D Greater Northwest","description":"The University of Washington is enrolling type 1 diabetes patients with diabetic kidney disease for the REMODEL T1D trial. Learn how semaglutide is being evaluated to protect renal function and reduce albuminuria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/","og_locale":"en_US","og_type":"article","og_title":"REMODEL T1D Semaglutide Kidney Study | Breakthrough T1D Greater Northwest","og_description":"The University of Washington is enrolling type 1 diabetes patients with diabetic kidney disease for the REMODEL T1D trial. Learn how semaglutide is being evaluated to protect renal function and reduce albuminuria.","og_url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/","og_site_name":"Greater Northwest Chapter","article_publisher":"https:\/\/www.facebook.com\/breakthrought1dHQ","article_published_time":"2024-10-18T19:13:01+00:00","article_modified_time":"2026-05-21T17:07:31+00:00","author":"Breakthrough T1D Author","twitter_card":"summary_large_image","twitter_creator":"@breakthrought1d","twitter_site":"@breakthrought1d","twitter_misc":{"Written by":"Breakthrough T1D Author","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/#article","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/"},"author":{"name":"Breakthrough T1D Author","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6"},"headline":"REMODEL T1D","datePublished":"2024-10-18T19:13:01+00:00","dateModified":"2026-05-21T17:07:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/"},"wordCount":253,"commentCount":0,"publisher":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/","name":"REMODEL T1D Semaglutide Kidney Study | Breakthrough T1D Greater Northwest","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#website"},"datePublished":"2024-10-18T19:13:01+00:00","dateModified":"2026-05-21T17:07:31+00:00","description":"The University of Washington is enrolling type 1 diabetes patients with diabetic kidney disease for the REMODEL T1D trial. Learn how semaglutide is being evaluated to protect renal function and reduce albuminuria.","breadcrumb":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/10\/18\/remodel-t1d\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/"},{"@type":"ListItem","position":2,"name":"REMODEL T1D"}]},{"@type":"WebSite","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#website","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/","name":"Greater Northwest Chapter","description":"","publisher":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization","name":"Breakthrough T1D","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/logo\/image\/","url":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","contentUrl":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","width":400,"height":400,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/breakthrought1dHQ","https:\/\/x.com\/breakthrought1d","https:\/\/www.youtube.com\/@breakthrought1d","https:\/\/www.instagram.com\/breakthrought1d\/","https:\/\/www.tiktok.com\/@breakthrought1dhq"]},{"@type":"Person","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6","name":"Breakthrough T1D Author","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","caption":"Breakthrough T1D Author"}}]}},"_links":{"self":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts\/9357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/users\/1317"}],"replies":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/comments?post=9357"}],"version-history":[{"count":0,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts\/9357\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/media?parent=9357"}],"wp:term":[{"taxonomy":"jdrf_topic","embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/topics?post=9357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}